Precigen, Inc. · NASDAQ:PGEN
Precigen — Intrexon — Corporate Update (November 2019)
14 slides from Precigen's corporate update, Nov 12, 2019

Slide 1: Precigen Business & Pipeline Update
Precigen Business & Pipeline Update 12 November 2019 Exhibit 99.1

Slide 2: Forward-looking statements
Forward-looking statements Precigen, Inc. is a subsidiary of Intrexon Corporation (Nasdaq: XON). Some of the statements made in this presentation are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking

Slide 3: Dr. Helen Sabzevari, President of Precigen
Dr. Helen Sabzevari President of Precigen

Slide 4: Precigen's technology platforms
CONTROL gene expression and regulation to drive safety CONSTRUCT powerful gene programs to drive efficacy DELIVER gene programs via viral and non-viral based approaches to drive lower costs Precigen’s technology platforms UltraVector® mbIL15 Sleeping Beauty system AttSiteTM recombinases AdenoVerseTM

Slide 5: Precigen's pipeline offers rapid value creation and potential for novel combinations
Precigen’s pipeline offers rapid value creation and potential for novel combinations Precigen pipeline as of November 2019

Slide 6: Disrupting the market: Precigen's transformative UltraCAR-T platform
Disrupting the market: Precigen’s transformative UltraCAR-T™ platform Reliance on viral vectors Complexity of manufacturing viral vectors Long and complex CAR-T cell manufacturing process Long delays for patients High cost of manufacturing Exhausted T cell phenotype Major challenges in solid tumor t

Slide 7: PRGN-3005 UltraCAR-T, a first-in-class therapy in ovarian cancer
PRGN-3005 UltraCAR-T™, a first-in-class therapy in ovarian cancer Advanced non-viral Sleeping Beauty system to co-express CAR, mbIL15 and kill switch Advanced stage platinum resistant ovarian cancer 300k diagnosed annually1/22k in US2 Stage IV survival as low as 20%3 Mucin 16 (MUC16) protein Overexp

Slide 8: PRGN-3005 UltraCAR-T: Phase 1 trial is enrolling patients
PRGN-3005 UltraCAR-T: Phase 1 trial is enrolling patients Clinical trial in collaboration with Uni. of WA & Fred Hutchinson Cancer Center Dose escalation study to determine safety and MTD Arm A: IP infusion Arm B: IV infusion 3x3 dose escalation for IP and IV infusion arms First cohort (dose level 1

Slide 9: PRGN-3006 UltraCAR-T, a first-in-class therapy in AML
PRGN-3006 UltraCAR-T™, a first-in-class therapy in AML Relapsed or refractory acute myeloid leukemia (AML) 20k diagnosed in US in 20181 Higher risk myelodysplastic syndrome (MDS) US incidence >10k per year2 Patient Population Advanced non-viral Sleeping Beauty system to co-express CAR, mbIL15 and ki

Slide 10: PRGN-3006 UltraCAR-T: Phase 1/1b trial is enrolling patients
PRGN-3006 UltraCAR-T: Phase 1/1b trial is enrolling patients Dose escalation study to determine safety and MTD Arm 1: NO lymphodepletion Arm 2: With lymphodepletion 3x3 dose escalation design followed by dose expansion phase at MTD for each arm Study in collaboration with Moffitt Cancer Center First

Slide 11: PRGN-2009 AdenoVerse immunotherapy showed anti-tumor activity in HPV+ head & neck cancer mouse model
PRGN-2009 off-the-shelf AdenoVerse™ immunotherapy showed robust anti-tumor activity in humanized mouse model of HPV+ head & neck cancer CD8+ T cells / mg tumor Increase in CD8+ T cell infiltration in tumor after PRGN-2009 treatment in mice PRGN-2009 immunotherapy effectively controls HPV+ head & nec

Slide 12: Multifunctional therapeutics overcome tumor microenvironment immunosuppression
Multifunctional therapeutics overcome tumor microenvironment immunosuppression and improve T cell function compared to anti-PD1 in preclinical mouse models PRGN-5001 exhibits superior anti-tumor effect compared to anti-PD1 in humanized mouse model of Head and Neck cancer PRGN-5002 exhibits superior

Slide 13: Portfolio Advancement in 2019
Portfolio Advancement in 2019 Rapidly advance preclinical and clinical programs þ þ þ þ þ Initiate PRGN-3006 UltraCAR-T TM Phase 1 trial in AML and MDS Rapidly advance PRGN-3005 UltraCAR-T TM for solid tumor Rapidly advance PRGN-2009 AdenoVerse TM immunotherapy for solid tumor Rapidly advance one in

Slide 14: EUG
EUG in t r e x on Pp ADY < )VANCI E ING C C IGS!
Source: SEC EDGAR · 8-K filed Nov 12, 2019
More decks from Precigen, Inc.
Q1 2026 Earnings Presentation21 slides · May 13, 2026
Corporate Update (August 2025)24 slides · Aug 18, 2025
39th Annual J.P. Morgan Healthcare Conference (January 2021)23 slides · Jan 13, 2021
Q2 2020 Earnings Presentation13 slides · Aug 10, 2020
Q1 2020 Earnings Presentation14 slides · May 6, 2020
Q4 2019 Earnings Presentation12 slides · Mar 2, 2020